Ads
related to: drugs that are competitive inhibitors for asthma patients chart for medication- Eosinophil Diseases
Learn About A Treatment For
Multiple Eosinophil-Driven Diseases
- Eosinophilic Asthma Info
Read About A Treatment For Severe
Eosinophilic Asthma To Learn More.
- Treatment Admin Options
Uncover An SEA Treatment That
May Fit Your Patient's Schedule.
- Dosing & Administration
View Dosing & Administration Info
For A Severe Asthma Medication.
- Right For Your Patients?
Patient Profiles & Data Are Ready.
See If This SEA Tx Is A Good Fit.
- Adverse Reaction Info
Explore Safety Information For
A Severe Asthma Treatment.
- Eosinophil Diseases
Search results
Results From The WOW.Com Content Network
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Drugs with muscarinic antagonist activity are widely used in medicine, in the treatment of low heart rate, overactive bladder, respiratory problems such as asthma and chronic obstructive pulmonary disease (COPD), and neurological problems such as Parkinson's disease and Alzheimer's disease.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Xolair, which is developed and co-promoted by Genentech and Novartis in the US, was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain people.
These drugs are used for the treatment of asthma. They may be useful either in the treatment or prevention of asthma attacks. ... Leukotriene pathway inhibitors (3 P ...
However, in March 2013, NICE issued "final draft guidance" about the allowance of omalizumab, recommending the medication as an option for treating severe, persistent allergic asthma in adults, adolescents and children following additional analyses and submission of a "patient access scheme" by Novartis, the manufacturer.
Ads
related to: drugs that are competitive inhibitors for asthma patients chart for medication